FTC Sues Drug Middlemen for Inflating Insulin Prices, Impacting Millions of Diabetics
Three significant pharmacy benefit managers are being sued by the FTC for allegedly utilizing improper rebate tactics to artificially inflate the cost of insulin. Millions of diabetic patients are impacted by the case, as their out-of-pocket expenses for life-saving prescriptions are greater. The Federal Trade Commission (FTC) has launched a complaint against OptumRx, Caremark, and…